Ophthalmic Business News

SAN FRANCISCO — In this Healio Video Perspective from Eyecelerator@AAO, Eris Jordan, OD, vice president of global clinical and medical affairs at Aurion Biotech, discusses the company’s novel cell therapy for corneal endothelial disease.

The AMA has assigned a Category 1 CPT code for Xipere, according to a press release from Bausch + Lomb.

SAN FRANCISCO — In this Healio Video Perspective from Eyecelerator@AAO, George Magrath, MD, MBA, MS, CEO of Ocuphire Pharma, provides an update on APX3330 for the treatment of diabetic retinopathy.

SAN FRANCISCO —The global ophthalmic market was worth an estimated $48.5 billion in 2023, according to Market Scope data presented here.

SAN FRANCISCO — To move forward successfully, venture capitalists interested in eye care need to be prepared to support longer development cycles, according to a speaker here.

In this Healio Video Perspective from Eyecelerator@AAO, Nick Curtis of Lensar discusses the Ally adaptive cataract treatment system’s implementation of Oertli’s Faros easyPhaco technology, which was submitted for FDA 510(k) clearance.

Aldeyra Therapeutics has entered into an exclusive option agreement with AbbVie for license to develop, manufacture and commercialize reproxalap, the company announced in a press release.

NEW YORK — In this Healio Video Perspective from OSN New York’s Disruptive Innovations Symposium, Nick Ruth of Sydnexis provides an update on a progressive myopia treatment for pediatric patients that is in development.

As millennial and older physicians can verify, the path to becoming a physician is long and arduous, filled with years of rigorous education, exams and residency training.

Bausch + Lomb launched SeeNa, an ophthalmic diagnostic system for refractive cataract practices that is integrated with the Eyetelligence surgical planning software, in the United States, according to a press release.